吲哚布芬联合尼可地尔对ACS患者PCI术后炎症因子、心肌损伤标志物和血小板功能的影响

doi:10.3969/j.issn.1006-5725.2024.12.016

Abstract

Abstract:

Objective To investigate the efficacy of indobuprofen combined with nicodil for the treatment of acute coronary syndromes （ACS） and the effects of percutaneous coronary intervention on patients Effects of myocardial injury markers， platelet function and inflammatory factors after intervention （PCI）. Method A total of 150 patients with ACS admitted to the hospital from January 2021 to December 2022 were divided into groups according to different treatment methods. The control group （n = 75） was given nicodil combined with antiplatelet therapy， and the study group （n = 75） was given indobufen combined with nicodil combined with antiplatelet therapy. Both groups were treated for 2 weeks. The clinical efficacy of the two groups was compared， the changes of myocardial injury markers， platelet function and inflammatory factors before and after treatment were monitored， and the total incidence of adverse reactions was recorded. Results The total effective rate of the group treated with nicodil combined with indobufen was 98.67% higher than that of the control group treated with nicodil alone， 90.67% （χ² = 4.754， P < 0.05）. The levels of myocardial injury markers such as cTnI and CK-MB in the study group after treatment were lower than those in the control group （t = 15.492， 3.250， P < 0.05）. The levels of platelet function indexes such as CD62p， CD63， GPⅡb/Ⅲa in the study group after treatment were lower than those in the control group （t = 2.034， 3.257， 2.221， P < 0.05）. The levels of CRP， TNF-α， IL-6 and other inflammatory factors in the study group were lower than those in the control group after treatment （t = 21.862， 3.378， 2.131， P < 0.05）. The total incidence of adverse reactions after treatment was 4.00% in the study group and 2.67% in the control group （P > 0.05）. Conclusion The efficacy of indobufien combined with nicodil in the treatment of ACS is better than that of nicodil alone， and it can improve myocardial injury and platelet function after PCI， inhibit the release of inflammatory factors， and the incidence of adverse reactions is lower.

Key words: indobuprofen, nicordil, acute coronary syndrome, markers of myocardial injury, platelet function, inflammatory factor

CLC Number:

R541

Shuhong RUI,Chenfang WANG,Yunhe LI,Junlan PAN,Jianlou WANG. Effects of indobuprofen combined with nicodil on inflammatory factors， myocardial injury markers and platelet function in patients with ACS after PCI[J]. The Journal of Practical Medicine, 2024, 40(12): 1706-1711.

Figures/Tables 6

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

Tab.6

References 28

1	王紫斓，涂应锋，于波. 支架置入术后再发急性冠状动脉综合征的研究进展［J］. 中国介入心脏病学杂志， 2021，29（8）：462-467. doi:10.3969/j.issn.1004-8812.2021.08.007 doi: 10.3969/j.issn.1004-8812.2021.08.007
2	AKTÜRK İ F， YILDIZ C， KARABULUT D，et al. Is the revascularisation strategy and outcome different in patients with acute coronary syndrome in COVID-19 pandemic era： a tertiary centre experience［J］. Acta Cardiol， 2021，77（8）：720-728. doi:10.1080/00015385.2021.1967614 doi: 10.1080/00015385.2021.1967614
3	董扬，张芬，王文标，等. 老年急性心肌梗死患者PCI和非PCI治疗预后比较［J］. 中华全科医学， 2022，159（4）：721-723.
4	FALLAHZADEH A， SHEIKHY A， AEIN A，et al. Outcome of Percutaneous Coronary Intervention in Old Patients Presenting with Acute Coronary Syndrome［J］. Arch Iran Med， 2022，25（8）：523-532. doi:10.34172/aim.2022.84 doi: 10.34172/aim.2022.84
5	边亚，刘广阔，李志涛，等. 尼可地尔对老年T2DM合并CHD患者心肌保护作用［J］. 中国急救复苏与灾害医学杂志， 2023，18（5）：583-586. doi:10.3969/j.issn.1673-6966.2023.05.005 doi: 10.3969/j.issn.1673-6966.2023.05.005
6	饶琰，雷阳. 尼可地尔联合双联抗血小板药物对急性NSTEMI患者PCI术后的影响［J］. 深圳中西医结合杂志， 2021，31（13）：162-164.
7	VINGE E， BJÖRKMAN S. Compared effects of the two antiinflammatory drugs indoprofen and lonazolac on thromboxane generation and on platelet aggregation， related to plasma concentrations after single oral doses［J］. Acta Pharmacol Toxicol，1986，59（3）：165-174. doi:10.1111/j.1600-0773.1986.tb00150.x doi: 10.1111/j.1600-0773.1986.tb00150.x
8	中华中医药学会内科分会心病专业委员会. 中医心病之心绞痛诊断与疗效标准［J］. 中国医药学报， 2004，19（10）：581-583. doi:10.3969/j.issn.1673-1727.2004.10.001 doi: 10.3969/j.issn.1673-1727.2004.10.001
9	中医临床诊疗指南制修订项目不稳定型心绞痛项目组. 不稳定型心绞痛中医诊疗专家共识［J］. 中医杂志， 2022，7（63）：695-700.
10	YAMAMOTO K， NATSUAKI M， MORIMOTO T， et al. Coronary Artery Disease Without Standard Cardiovascular Risk Factors［J］. Am J Cardiol， 2022，164：34-43. doi:10.1016/j.amjcard.2021.10.032 doi: 10.1016/j.amjcard.2021.10.032
11	刘江萍，木胡牙提. 急性冠脉综合征流行病学及危险因素的研究进展［J］. 国际心血管病杂志， 2019，46（1）：1-3，7. doi:10.3969/j.issn.1673-6583.2019.01.001 doi: 10.3969/j.issn.1673-6583.2019.01.001
12	张嵚垚，马淑梅. 静脉注射尼可地尔对行经皮冠状动脉介入治疗的不稳定性心绞痛患者的心肌保护作用［J］. 实用药物与临床， 2020，23（1）：77-81.
13	张紫萍，方广，郭秀彩. 从《冠心病合理用药指南》看尼可地尔在冠心病治疗中的作用［J］. 实用医学杂志， 2020，36（22）：3033-3037. doi:10.3969/j.issn.1006-5725.2020.22.001 doi: 10.3969/j.issn.1006-5725.2020.22.001
14	崔高伟，金会群，张利卫，等. 尼可地尔联合双联抗血小板药物治疗急性非ST段抬高型心肌梗死PCI术后患者的效果［J］. 河南医学研究， 2021，30（34）：6477-6479. doi:10.3969/j.issn.1004-437X.2021.34.047 doi: 10.3969/j.issn.1004-437X.2021.34.047
15	徐辉. 吲哚布芬在经皮冠状动脉支架植入术后急性冠脉综合征患者中的疗效与安全性研究［D］. 青岛：青岛大学，2024.
16	SHEN L， QIU L， LIU J，et al. Clinical Implications of Nicorandil Combined with Trimetazidine in Patients with Coronary Heart Disease： A Real-World Observational Study［J］. Adv Ther， 2021，39（1）：655-673. doi:10.1007/s12325-021-01987-1 doi: 10.1007/s12325-021-01987-1
17	CHOE J C， OH J H， LEE H C，et al. The effect of nicorandil on cardiac function and clinical outcomes in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention： a randomised trial［J］. Acta Cardiol， 2023，78（8）：880-888. doi:10.1080/00015385.2022.2129592 doi: 10.1080/00015385.2022.2129592
18	PAN Y， MENG X， CHEN W， et al.Indobufen versus aspirin in acute ischaemic stroke （INSURE）： rationale and design of a multicentre randomised trial［J］. Stroke Vasc Neurol， 2022， 7（5）：457-461. doi:10.1136/svn-2021-001480 doi: 10.1136/svn-2021-001480
19	QUESADA O， ELBOUDWAREJ O， NELSON M D，et al. Ultra-high sensitivity cardiac troponin-I concentration and left ventricular structure and function in women with ischemia and no obstructive coronary artery disease［J］. Am Heart J Plus， 2022，13：100115. doi:10.1016/j.ahjo.2022.100115 doi: 10.1016/j.ahjo.2022.100115
20	WU H， XU L， ZHAO X，et al. OPTION Investigators. Indobufen or Aspirin on Top of Clopidogrel After Coronary Drug-Eluting Stent Implantation （OPTION）： A Randomized， Open-Label， End Point-Blinded， Noninferiority Trial［J］. Circulation， 2023，147（3）：212-222. doi:10.1161/circulationaha.122.062762 doi: 10.1161/circulationaha.122.062762
21	LEE C C， CHANG S N， TEHRANI B，et al. Use of nicorandil is associated with increased risk of incident atrial fibrillation［J］. Aging （Albany NY）， 2022，14（17）：6975-6992. doi:10.18632/aging.204259 doi: 10.18632/aging.204259
22	代世摩，戚志勇，齐保振，等. 沙库巴曲缬沙坦对血小板活化，动脉血栓形成的作用［J］. 中国分子心脏病学杂志， 2023，23（3）：5380-5386.
23	SHI Q P， LUO X Y， ZHANG B，et al. Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention： An open-label crossover study［J］. Front Pharmacol，2022，13：950-979. doi:10.3389/fphar.2022.950719 doi: 10.3389/fphar.2022.950719
24	HUANG D， WU H， ZHOU J， et al. Intravenous nicorandil during primary percutaneous coronary intervention in patients with ST-Elevation myocardial infarction： Rationale and design of the Clinical Efficacy and Safety of Intravenous Nicorandil （CLEAN） trial［J］. Am Heart J，2021，244：86-93. doi:10.1016/j.ahj.2021.11.005 doi: 10.1016/j.ahj.2021.11.005
25	PAN Y， MENG X， CHEN W，et al. Indobufen versus aspirin in acute ischaemic stroke （INSURE）： rationale and design of a multicentre randomised trial［J］. Stroke Vasc Neurol，2022，7（5）：457-461. doi:10.1136/svn-2021-001480 doi: 10.1136/svn-2021-001480
26	张慧垒，邢疆波，李长路. 益气舒心丸联合他汀类药物对ACS病人PCI术后HSP60，hs-CRP，TNF-α指标的影响［J］. 中西医结合心脑血管病杂志， 2020，18（19）：3234-3235.
27	LI K， YANG H， JIANG Z，et al. Effect of proximal femoral nail antirotation on clinical outcome， inflammatory factors and myocardial injury markers in patients with femoral trochanteric fracture［J］. Am J Transl Res， 2022，14（7）：4795-4803.
28	SHI L， CHEN L， QI G，et al. Effects of Intracoronary Nicorandil on Myocardial Microcirculation and Clinical Outcomes in Patients with Acute Myocardial Infarction： A Meta-Analysis of Randomized Controlled Trials［J］. Am J Cardiovasc Drugs，2020，20（2）：191-198. doi:10.1007/s40256-019-00368-y doi: 10.1007/s40256-019-00368-y

组别	例数	年龄（岁）	体质量指数（kg/m²）	发病时间（h）	严重程度（例）
组别	例数	年龄（岁）	体质量指数（kg/m²）	发病时间（h）	急性心肌梗死	不稳定型心绞痛
研究组	75	61.27 ± 4.14	23.25 ± 0.61	5.27 ± 4.14	39	36
对照组	75	61.14 ± 4.21	23.31 ± 0.63	5.14 ± 4.21	40	35
χ²/t值		0.191	0.593	0.191	0.027
P值		0.849	0.554	0.849	0.970

组别	例数	显效	有效	无效	总有效率
研究组	75	32（42.67）	42（56.00）	1（1.33）	74（98.67）
对照组	75	25（33.33）	43（57.33）	7（9.33）	68（90.67）
χ²值					4.754
P值					0.029

组别	例数	cTnI(ng/mL)		t值	P值	CK-MB(ng/mL)		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
研究组	75	0.13 ± 0.05	0.04 ± 0.01	15.286	0.000	6.21 ± 1.22	3.97 ± 1.04	12.101	0.000
对照组	75	0.14 ± 0.06	0.08 ± 0.02	8.216	0.000	6.13 ± 1.18	4.53 ± 1.07	20.777	0.000
t值		1.071	15.492			0.408	3.250
P值		0.286	0.001			0.684	0.001

组别	例数	CD62p(%)		t值	P值	CD63(%)		t值	P值	GPⅡb /Ⅲa(%)		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
研究组	75	18.23 ± 3.31	22.62 ± 5.31	5.870	0.000	6.21 ± 1.17	8.43 ± 2.81	6.012	0.000	79.24 ± 8.15	89.28 ± 9.33	6.781	0.000
对照组	75	18.45 ± 3.35	24.47 ± 5.45	7.873	0.000	6.26 ± 1.21	10.05 ± 3.07	9.609	0.000	79.33 ± 8.21	93.16 ± 11.25	8.308	0.000
t值		0.391	2.034			0.249	3.257			0.065	2.221
P值		0.697	0.044			0.804	0.001			0.948	0.028

组别	例数	CRP(mg/L)		t值	P值	TNF-α(ng/L)		t值	P值	IL-6(pg/mL)		t值	P值
组别	例数	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值	治疗前	治疗后	t值	P值
研究组	75	7.82 ± 2.13	2.32 ± 0.53	20.965	0.000	41.62 ± 11.57	32.16 ± 8.27	5.565	0.000	30.24 ± 4.51	19.81 ± 3.14	15.879	0.000
对照组	75	7.76 ± 2.12	5.37 ± 1.04	8.468	0.000	42.01 ± 11.64	37.45 ± 10.16	2.469	0.015	30.48 ± 4.67	21.17 ± 4.32	12.244	0.000
t值		0.167	21.862			0.199	3.378			0.309	2.131
P值		0.868	0.000			0.843	0.001			0.758	0.035

Effects of indobuprofen combined with nicodil on inflammatory factors， myocardial injury markers and platelet function in patients with ACS after PCI

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 28

Related Articles 15

Recommended Articles

Metrics

Comments

组别	例数	食欲不振	心悸	胃肠道反应	头晕	恶心呕吐	总发生率
研究组	75	1（1.33）	0（0）	0（0）	1（1.33）	1（1.33）	3（4.00）
对照组	75	1（1.33）	0（0）	0（0）	1（1.33）	0（0）	2（2.67）
χ²值							0.207
P值							0.649

[1]	Liangxi LU,Hong SHI,Zhimin HUANG,Jie LU,Wenjie. WANG. Exploring mechanism of TLR4/NF⁃κB⁃NLRP3 inflammasome signaling pathway in experimental autoimmune prostatitis rats [J]. The Journal of Practical Medicine, 2025, 41(6): 800-805.
[2]	Tianzhong PENG,Xuedi HUANG,Xingzhen LIN,Juan YUAN,Feng ZHOU,Langhui LIU,Qi′nan ZHAN,Manhua. ZHU. Effect of Kaiqiao Xingshen acupuncture combined with Buyang Huanwu decoction on IL⁃2， MMP⁃9， BDNF， and cerebral blood flow in patients with cerebral hemorrhage during recovery period （Qi deficiency and blood stasis syndrome） [J]. The Journal of Practical Medicine, 2025, 41(3): 428-433.
[3]	Chunyan LI,Ting XIAO,Bangcui WU,Yong CHEN,Mei TIAN. PKCβ inhibitor modulates macrophage phenotype and affects kidney ischemia-reperfusion injury during transplantation [J]. The Journal of Practical Medicine, 2025, 41(1): 23-29.
[4]	Yuying HU,Jinming ZHU,Jie LIU,Yawen PAN,Qian ZHANG,Jinqiu FENG. Expression and significance of miR⁃223⁃3p in serum of pregnant women with preterm premature rupture of membranes [J]. The Journal of Practical Medicine, 2024, 40(9): 1275-1279.
[5]	Ling XIAO,Chunlei GAO,Wei GUO,Ning WANG,Xuan ZHANG,Ming. LIU. Codonopsis polysaccharide protected LPS⁃induced acute lung injury by inhibiting MAPK/NF⁃κB signaling pathway in mice [J]. The Journal of Practical Medicine, 2024, 40(7): 948-954.
[6]	Lihong DING,Shijia GENG,Yujie WANG. Effects of wedelobata on apoptosis and secretion of inflammatory cytokines in the alveolar epithelium infected by Streptococcus pneumonia [J]. The Journal of Practical Medicine, 2024, 40(3): 316-320.
[7]	Tianyue YU,Qian GUO,Hao HU,Yujing SU,Jianhua CHEN. Advances in oxidative stress⁃related pathways with diagnostic and predictive value in schizophrenia [J]. The Journal of Practical Medicine, 2024, 40(20): 2935-2940.
[8]	Bin ZHANG,Wei HU,Rongzhen TAN,Panpan YANG,Jun HU,Zhong YUAN,Gongtao. JIANG. Effects of Yishen Huayu Xugu prescription combined with Dixumab on IL-6， β-CTX and bone mineral density in elderly patients operated for osteoporotic lumbar vertebral compression fractures [J]. The Journal of Practical Medicine, 2024, 40(19): 2766-2771.
[9]	Weifeng ZHANG,Hailong MA,Jinling. ZHANG. Effect of PCSK9 inhibitors on inflammation levels and ventricular remodeling after PCI in ST⁃elevation acute myocardial infarction [J]. The Journal of Practical Medicine, 2024, 40(15): 2142-2147.
[10]	Xuan QIU,Yishajiang SHAREZATI,Yulan CHEN,Mengmeng WANG,Yu LI,Tulahong GULINAZI,Abuhan ZUBAIDAN,Abulizi ALIYA,Xingchen WANG. Effect of transient receptor potential channel 5 on myocardial pyroptosis in intermittent hypoxia [J]. The Journal of Practical Medicine, 2024, 40(12): 1637-1642.
[11]	Yinbi ZHENG,Yiming SHAO,Zhaoji LI,Shiting LI,Mingdi CHEN,Wenchi ZENG,Hongyu. DONG. Effect of dexmedetomidine on renal function in patients with septic⁃associated acute kidney injury： A cohort study [J]. The Journal of Practical Medicine, 2024, 40(10): 1423-1428.
[12]	Dechao LI,Mingjin ZHANG,Yibi LAN,Chunlei MA,Weijin. FU. Expression of allograft inflammatory factor⁃1 in the testicular model of diabetes mellitus rats [J]. The Journal of Practical Medicine, 2024, 40(1): 65-71.
[13]	XU Hong, SUN Wei, LIAO Zonghua, LI Mingmin.. Curative effect of high flow humidified oxygen delivery device combined with glutathione on AECOPD patients [J]. The Journal of Practical Medicine, 2023, 39(5): 607-612.
[14]	GAO Yujiu, HU Rong, FANG Chen, LI Panpan, MENG Xiang, GUO Xingrong, FENG Ying.. ANGPTL8 knockout alleviates DEN⁃induced acute liver injury [J]. The Journal of Practical Medicine, 2023, 39(3): 278-284.
[15]	RUI Shuhong, WANG Chenfang, LI Yunhe, PAN Junlan, WANG Jianlou. . Effects of indobufen combined with clopidogrel on vascular endothelial function，inflammatory factors and oxidative stress in patients with acute coronary syndrome [J]. The Journal of Practical Medicine, 2023, 39(12): 1551-1555.